ImmunoGen, Surprisingly Quiet Ahead of FDA Decision

Published February 14, 2013

ImmunoGen, Surprisingly Quiet Ahead Of FDA Decision

Filed under: drug addiction treatment statistics

… standard-of-care Herceptin (trastuzumab) and a taxane. This means that the drug will not be able to penetrate the breast/gastric cancer as thoroughly as a front-line therapy, which would hypothetically limit its total revenue potential. … In the …
Read more on Seeking Alpha

AVEO, Astellas report final overall survival results from TIVO-1

Filed under: drug addiction treatment statistics

No statistical difference between the two arms (HR=1.245, p=0.105) was observed. The OS data are included in the tivozanib New Drug Application (NDA) filing and will be presented at the 2013 American Society for Clinical Oncology Genitourinary Cancers …
Read more on pharmabiz.com

Early diagnosis and proper treatment of Rheumatoid Arthritis cuts risk of …

Filed under: drug addiction treatment statistics

She noted though that there has been significant progress in the treatment of rheumatoid arthritis in the past decade, especially in the field of modern biotech medications. There are some biological drugs that work to get rid of lymphocytes that play …
Read more on AME Info (press release)